In this article, we will discuss Necitumumab (Dosage Overview). So, let’s get started.


Squamous Non-Small Cell Lung Cancer (NSCLC)
Necitumumab is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Limitation of Use
Necitumumab is not indicated for treatment of non-squamous non-small cell lung cancer.


Recommended Dose and Schedule
The recommended dose of Necitumumab is 800 mg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion. Continue Necitumumab until disease progression or unacceptable toxicity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.